# US 12,766,131 B2 · Compostions and methods for treating prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,766,131 B2
- Document ID: US12766131B2
- Status: Granted
- Kind: B2
- Application number: 18/218,930
- Filed: 2023-07-06
- Published: 2024-01-11
- Granted: 2026-10-20
- Earliest claimed: 2022-07-08
- Assignees: The Regents of the University of Michigan; Oregon Health & Science University
- Applicants: The Regents of the University of Michigan; Oregon Health & Science University
- Inventors: Joshi Alumkal; Zheng Xia
- Web page: https://patentgrep.com/patent/US12766131B2

## CPC

- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61P 35/00: Antineoplastic agents
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure relates to compositions, systems, and methods for treating cancer. In particular, the present disclosure relates to compositions, systems, and methods for characterizing and treating prostate cancer (e.g., castration-resistant prostate cancer).

## Claims

### Claim 1

A method for treating prostate cancer, comprising:
a) assaying a sample from a subject diagnosed with prostate cancer for the level of expression of the genes RING FINGER PROTEIN 43 (RNF43), SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDE F (SNRPF), TRAB DOMAIN-CONTAINING PROTEIN 2A (TRABD2A), NADH-UBIQUINONE OXIDOREDUCTASE SUBUNIT A12 (NDUFA12), GROWTH ARREST-SPECIFIC 2-LIKE 3 (GAS2L3), RIBOSOMAL PROTEIN S24 (RPS24), DNA REPLICATION HELICASE/NUCLEASE 2 (DNA2), RETINITIS PIGMENTOSA (RP5-857K21.10), POC1 CENTRIOLAR PROTEIN B (POC1B), ADENOSINE KINASE (ADK), ATP SYNTHASE F1, SUBUNIT BETA (ATP5B), EXPORTIN, tRNA (XPOT), SOLUTE CARRIER ORGANIC ANION TRANSPORTER FAMILY, MEMBER 1B3 (SLCO1B3), and RHO-RELATED BTB DOMAIN-CONTAINING PROTEIN 1 (RHOBTB1);
b) calculating a lineage plasticity score based on said level of gene expression;
c) identifying the subject with a high lineage plasticity score; and
d) administering treatment that does not include an androgen receptor signaling inhibitor treatment to said subject, wherein the treatment includes a prostate cancer treatment that is chemotherapy, radiation, surgery and/or immunotherapy.

### Claim 2

A method for treating prostate cancer, comprising:
a) assaying a sample from a subject diagnosed with prostate cancer for the level of expression of the genes RNF43, SNRPF, TRABD2A, NDUFA12, GAS2L3, RPS24, DNA2, RP5-857K21.10, POC1B, ADK, ATP5B, XPOT, SLCO1B3, and RHOBTB1;
b) calculating a lineage plasticity score based on said level of gene expression;
c) identifying the subject with a low lineage plasticity score; and
d) administering an androgen receptor signaling inhibitor treatment to said the subject.

### Claim 3 (depends on 2)

The method of claim 2, wherein said treatment is enzalutamide.

### Claim 4 (depends on 1)

The method of claim 1, wherein said prostate cancer is castration-resistant prostate cancer (CRPC).

### Claim 5 (depends on 1)

The method of claim 1, wherein said sample is blood, urine, or prostate cells.